C
Cathryn S Brock
Researcher at Charing Cross Hospital
Publications - 37
Citations - 2803
Cathryn S Brock is an academic researcher from Charing Cross Hospital. The author has contributed to research in topics: Temozolomide & Cancer. The author has an hindex of 17, co-authored 36 publications receiving 2515 citations. Previous affiliations of Cathryn S Brock include Imperial College London & Queen Mary University of London.
Papers
More filters
Journal ArticleDOI
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials
Edward S. Newlands,Malcolm F. G. Stevens,Stephen R. Wedge,Richard T. Wheelhouse,Cathryn S Brock +4 more
TL;DR: This poster presents a poster presented at the 2016 American Academy of Medical Oncology Congress on Wednesday, 3 March 2016 calling for awareness of the importance of informed consent in the selection of patients for cancer treatment.
Journal ArticleDOI
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
David J. Pinato,David J. Pinato,Sarah Howlett,Diego Ottaviani,Heather Urus,Aisha Patel,Takashi Mineo,Takashi Mineo,Cathryn S Brock,Danielle Power,Olivia Hatcher,Alison Falconer,Manasi Ingle,Anna Brown,Dorothy Gujral,Sarah Partridge,Naveed Sarwar,Michael Gonzalez,Maggie Bendle,Conrad R. Lewanski,Thomas Newsom-Davis,Elias Allara,Elias Allara,Mark Bower +23 more
TL;DR: PATB therapy but not cATB Therapy is associated with a worse treatment response and OS in unselected patients treated with ICIs in routine clinical practice, suggesting that pATB-mediated alterations of gut microbiota as a determinant of poorer outcome following ICI treatment.
Journal Article
Phase I Trial of Temozolomide Using an Extended Continuous Oral Schedule
Cathryn S Brock,Edward S. Newlands,Steven R. Wedge,Mark Bower,Helen H. Evans,Iain Colquhoun,Mary Roddie,M.G. Glaser,Maureen H. Brampton,Gordon J. S. Rustin +9 more
TL;DR: Toxicity was greatest in higher dose cohorts, with a resultant maximum tolerated dose of 85 mg/m2/day, whereas lower dose cohorts tolerated the schedule well, and the area under the temozolomide plasma versus time curve was noncumulative between the first and last week of the schedule.
Journal ArticleDOI
EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.
Mark Bower,Edward S. Newlands,L. Holden,D Short,Cathryn S Brock,G.J.S. Rustin,R. H. J. Begent,Kd Bagshawe +7 more
TL;DR: EMA/CO is an effective and well-tolerated regimen for high-risk GTT and more than half of the women will retain their fertility; however, there is a small but significant risk of second malignancy.
Journal ArticleDOI
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Edward S. Newlands,S.M. O'Reilly,M.G. Glaser,Mark Bower,H. Evans,Cathryn S Brock,M. H. Brampton,I. Colquhoun,P. Lewis,J.M. Rice-Edwards,R.D. Illingworth,P.G. Richards +11 more
TL;DR: In conclusion, temozolomide given in this schedule has activity against high grade glioma, however, studies evaluating chemotherapy in primary brain tumours should include a quality-of-life/performance status evaluation in addition to CT or MRI scanning assessment.